Literature DB >> 15767499

Molecular pathogenesis of Parkinson disease.

Jason L Eriksen1, Zbigniew Wszolek, Leonard Petrucelli.   

Abstract

Parkinson disease (PD), the most common neurodegenerative movement disorder, is characterized by an extensive and progressive loss of dopaminergic neurons in the substantia nigra pars compacta. One of the pathological hallmarks of PD is the presence of Lewy bodies, intracellular inclusions of aggregated alpha-synuclein. Although the cause and pathogenesis of selective loss of dopamine neurons and the accumulation of alpha-synuclein in PD remain elusive, growing lines of evidence from environmental risk factors and early-onset genetics point to a convergence between energy metabolism and the disposal of damaged proteins in the development of PD. These findings suggest that impairments in mitochondrial and ubiquitin-proteasome system function can significantly contribute to the pathogenesis of PD. This review will summarize recent insights gained from genetic and environmental studies of PD that underscore this association.

Entities:  

Mesh:

Year:  2005        PMID: 15767499     DOI: 10.1001/archneur.62.3.353

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  58 in total

1.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway.

Authors:  José M Bravo-San Pedro; Mireia Niso-Santano; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Ana Aiastui-Pujana; Ana Gorostidi; Vicente Climent; Rakel López de Maturana; Rosario Sanchez-Pernaute; Adolfo López de Munain; José M Fuentes; Rosa A González-Polo
Journal:  Cell Mol Life Sci       Date:  2012-07-08       Impact factor: 9.261

2.  Head injury, α-synuclein Rep1, and Parkinson's disease.

Authors:  Samuel M Goldman; Freya Kamel; G Webster Ross; Sarah A Jewell; Grace S Bhudhikanok; David Umbach; Connie Marras; Robert A Hauser; Joseph Jankovic; Stewart A Factor; Susan Bressman; Kelly E Lyons; Cheryl Meng; Monica Korell; Diana F Roucoux; Jane A Hoppin; Dale P Sandler; J William Langston; Caroline M Tanner
Journal:  Ann Neurol       Date:  2012-01       Impact factor: 10.422

3.  The Neuroprotective Effect of Erythropoietin on Rotenone-Induced Neurotoxicity in SH-SY5Y Cells Through the Induction of Autophagy.

Authors:  Wooyoung Jang; Hee Ju Kim; Huan Li; Kwang Deog Jo; Moon Kyu Lee; Hyun Ok Yang
Journal:  Mol Neurobiol       Date:  2015-07-09       Impact factor: 5.590

Review 4.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

5.  Inhibition of Mitochondrial Clearance and Cu/Zn-SOD Activity Enhance 6-Hydroxydopamine-Induced Neuronal Apoptosis.

Authors:  Sua In; Chang-Won Hong; Boyoung Choi; Bong-Geum Jang; Min-Ju Kim
Journal:  Mol Neurobiol       Date:  2015-01-29       Impact factor: 5.590

Review 6.  Rifampicin and Parkinson's disease.

Authors:  Wei Bi; Lihong Zhu; Xiuna Jing; Yanran Liang; Enxiang Tao
Journal:  Neurol Sci       Date:  2012-07-21       Impact factor: 3.307

7.  Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson's disease-linked mutants.

Authors:  Cintia Roodveldt; Adahir Labrador-Garrido; Elena Gonzalez-Rey; Rafael Fernandez-Montesinos; Marta Caro; Christian C Lachaud; Christopher A Waudby; Mario Delgado; Christopher M Dobson; David Pozo
Journal:  PLoS One       Date:  2010-10-26       Impact factor: 3.240

8.  Effects of Various Flavonoids on the α-Synuclein Fibrillation Process.

Authors:  Xiaoyun Meng; Larissa A Munishkina; Anthony L Fink; Vladimir N Uversky
Journal:  Parkinsons Dis       Date:  2010-01-28

9.  Ashkenazi Parkinson's disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries.

Authors:  Anat Bar-Shira; Carolyn M Hutter; Nir Giladi; Cyrus P Zabetian; Avi Orr-Urtreger
Journal:  Neurogenetics       Date:  2009-03-13       Impact factor: 2.660

10.  Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease.

Authors:  Vanesa Sanchez-Guajardo; Fabia Febbraro; Deniz Kirik; Marina Romero-Ramos
Journal:  PLoS One       Date:  2010-01-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.